Close Menu

NEW YORK – Although population screening for cancer-related founder mutations in BRCA1/2 in individuals with Ashkenazi Jewish ancestry is possible in American cities, new research suggests there are still hurdles when it comes to reaching participants and their healthcare providers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.